Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2021 | Treating triple refractory CLL in patients with HIV

Barbara Eichhorst • 8 Jun 2021
ICML 2021
Chronic Lymphocytic Leukemia Leukemia CAR-T

Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, summarizes a case study involving a patient with triple refractory chronic lymphocytic leukemia (CLL). In addition to being refractory to BTK and BCL2 inhibitors, the man was HIV positive. Chimeric antigen receptor (CAR) T-cell therapy is typically offered for patients with relapsed/refractory CLL, but was not possible for the patient as harvesting T cells would be an obstacle. Allogeneic stem cell transplant was consequently determined to be the best course of action. This is interview took place during the 2021 International Conference on Malignant Lymphoma (16-ICML).

More from Barbara Eichhorst

1:05
Risk-factors for Richter’s transformation
Barbara Eichhorst • 10 Dec 2023
2:01
Updated follow-up results of the Phase III GAIA/CLL13 trial
Barbara Eichhorst • 10 Dec 2023
2:08
CLL-RT1 trial: primary endpoint analysis of tislelizumab plus zanubrutinib in patients with RT
Barbara Eichhorst • 10 Dec 2023
1:14
Current trials of interest in CLL
Barbara Eichhorst • 7 Oct 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals